Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A urethral sphincter injections in women with chronic urinary retention or voiding dysfunction due to Fowler's syndrome
2008-004858-33Phase 2Completed
- Sponsor
- University College London
- Start
- Nov 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in acute urinary retention, Urethral instability, chronic urinary retention (CUR) and 2 more, sponsored by University College London. Primary endpoint: Restoration of voiding or improvement in urinary flow. Started Nov 2008; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
acute urinary retentionUrethral instabilitychronic urinary retention (CUR)Micturition disorderIntrinsic Sphincter Deficiency (ISD)
Beyond the preview
Go deeper on 2008-004858-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004858-33.